SHARON, Pa.,
May 24 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (Pink Sheets:
NNLX
- News)
announced today that it has filed a total of 5 patents (2
U.S., 2 provisional U.S. and 1 international) for its BioNanoChannel(TM)
Technology for rapid bacterial detection and identification.
This is a unique technology developed by NanoLogix that
allows for the identification of bacteria strains in minutes
to hours in comparison to normal 1 to more days for conventional
methods such as Petri dishes. The current Petri Dish market
alone is a multi billion dollar industry.
The BioNanoChannel(TM)
technology utilizes extremely small (2 to 25 Microns)
channels to trap bacteria and then applies proprietary
NanoLogix techniques covered in the patent applications
to detect and or identify the bacteria in extremely small
concentrations down to a single cell. In hospitals quick
identification of bacteria can be a matter of life or
death, and doctors are forced to use damaging broad spectrum
antibiotics until the infection is identified. The BioNanoChannel(TM)
technology is simple and user-friendly (doesn't need sophisticated
opto-electronic equipment), and is applicable to a large
number of different liquid, solid, and bioaerosol samples.
The apparatus excluding a microscope can be held in one's
hand.
"These five patent
applications are the cumulative result of eight years
of brilliant work by Dr. Sergey Gazenko, who is the world's
leading expert in the field of BioNanoChannel(TM) Technology,"
said Bret Barnhizer, CEO and Chairman of NanoLogix. "We
anticipate his efforts leading to NanoLogix increasing
its technology advantage in yet another area that is separate
from, but complementary to, our efforts in hydrogen bioreactor
and other medical technology development."
NanoLogix
is currently finalizing the tooling for the first production
run of the BioNanoChannel(TM) device. In addition to medical
applications, there are similar needs in the food industry
and BioDefense for rapid bacteria detection and ID. NanoLogix
is in contact with the United States government in regard
to rapid, portable and affordable Anthrax identification.
One advantage the BioNanoChannel(TM) has over competing
technologies such as PCR (Polymerase Chain Reaction) is
its ability to determine whether the spores or cells are
still alive, which is critical for decontamination. Dana
Allen, Vice President of Strategic Partnering of NanoLogix,
stated, "Regulatory approvals are required for the
BioNanoChannel(TM) before it can be sold in the general
diagnostic market. At this point we can sell it for research,
pursue partnering agreements, pursue grants and contract
with entities such as our government for BioDefense and
other needs while we pursue regulatory approvals. Approvals
for diagnostic devices are much easier than for drugs."
About
NanoLogix, Inc.
NanoLogix
is an industry innovator in the research, development,
and commercialization of nano-biotechnologies, applications
and processes. The Company has developed and owns or has
rights to 31 patents related to various medical technologies,
5 of which also have hydrogen-generation aspects. In the
past year the Company has filed an additional 28 patent
applications for discoveries related to hydrogen bioreactors,
medical testing, and innovative medical treatments potentially
related to leukemia and sepsis. NanoLogix is presently
operating a hydrogen bioreactor at Welch's Food. NanoLogix-developed
patents are used to design and market diagnostic test
kits for use in early detection of the bacteria present
in infectious and noninfectious human diseases such as
tuberculosis, pneumonia, HIV/AIDS, cancer, and cystic
fibrosis. The company also owns a patent for the non-toxic
induction of apoptosis ('cell suicide') for the treatment
of cancer. BioNanoChannel is a Trademark of NanoLogix,
Inc., for more information on the Company, visit
nanologixinc.com.
This press release contains
statements, which may constitute "forward- looking
statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as
amended by the Private Securities Litigation Reform Act
of 1995. Those statements include statements regarding
the intent, belief or current expectations of NanoLogix,
Inc., and members of its management as well as the assumptions
on which such statements are based. Prospective investors
are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks
and uncertainties, and that actual results may differ
materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update
or revise forward-looking statements to reflect changed
assumptions, the occurrence of unanticipated events or
changes to future operating results.
